Relmada Therapeutics

Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock See more here

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results  See more here

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential  - All tested doses of REL-1017, including the maximum tolerated dose, showed a highly statistically significant difference in abuse potential vs. oxycodone with p-values <0.001 - Company to host conference call at 8:30 AM Eastern Time…

Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC  See more here

Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder  See more here

Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder  See more here

Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones  See more here

Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®  See more here

Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder Phase 3 Program Can Advance and the Company Plans to Initiate Registration Studies in the Fourth Quarter of 2020  See more here

Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations See more here